Abstract Purpose Tumor Treating Fields (TTFields) therapy, an electric field-based cancer
treatment, became FDA-approved for patients with newly diagnosed glioblastoma (GBM) in …

Glioblastoma (GBM) is an aggressive malignancy of the central nervous system (CNS) that
remains incurable despite the multitude of improvements in cancer therapeutics. The …

Simple Summary Despite the complete treatment with surgery, chemotherapy and
radiotherapy, patients with glioblastoma have a devasting prognosis. Although the role of …

Simple Summary Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-
year survival rate (< 5%). In the last decades, the concomitant use of two non-invasive …

Introduction Glioblastoma (GBM) is the most common malignant primary central nervous
system cancer in adults. The objective of the Multi-Arm GlioblastoMa Australasia (MAGMA) …

Background Tumor necrosis factor (TNF) is an inflammatory cytokine that can coordinate
tissue homeostasis by co-regulating the production of cytokines, cell survival, or death. It …

Introduction: Despite decades of clinical trials utilizing conventional and novel therapeutics,
the effective treatment of glioblastoma remains one of the most formidable challenges in …

Introduction Glioblastoma (GBM) is the most common malignant primary central nervous
system cancer in adults. The objective of the Multi-Arm GlioblastoMa Australasia (MAGMA) …

In this study we evaluated the benefit on survival of the combination of MGMT methylation
and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from …

[ES] Los tumores cerebrales son una de las enfermedades más devastadoras en la
actualidad por el importante deterioro cognitivo que sufren los pacientes, la elevada tasa de …